Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.61 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494946 | 0.85 | PPARG (0.62) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4249329 | 0.85 | RAB9A (0.71) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL7294922 | 0.84 | NPC1 (0.71) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6078205 | 0.84 | NPC1 (0.75) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6365067 | 0.84 | MAPT (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL2681347 | 0.83 | NPC1 (0.80) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL7513604 | 0.83 | TRPV1 (0.83) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6557523 | 0.82 | NPC1 (0.77) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL28910371 | 0.82 | TRPV1 (0.71) | NPC1RAB9AKMT2AMAPK1KCNQ3 | |
| SCHEMBL8460312 | 0.82 | NPC1 (0.78) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885MAPT 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.